Positron emission tomography neuroimaging in Amyotrophic lateral sclerosis: What is new?

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 58, Issue 4, 2014, Pages 344-354

  Quartuccio, N ^a   Van Weehaeghe, D ^b   Cistaro, A ^c,d,e   Jonsson, C ^f   Van Laere, K ^b   Pagani, M ^e,f  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Euromedic Inc   (Italy)

^d PET Pediatric AIMN Inter Group   (Italy)

^e INSTITUTE OF COGNITIVE SCIENCES AND TECHNOLOGIES   (Italy)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Amyotrophic lateral sclerosis; Bulbar; Positron emission tomography; Spinal

Indexed keywords

FLUMAZENIL C 11; FLUORODEOXYGLUCOSE F 18; TRACER; RADIOISOTOPE;

AMYOTROPHIC LATERAL SCLEROSIS; BRAIN REGION; HUMAN; MUTATION; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIMARY LATERAL SCLEROSIS; REVIEW; WHITE MATTER; ALGORITHM; ARTIFICIAL INTELLIGENCE; BRAIN; DIAGNOSTIC USE; INFLAMMATION; PROCEDURES; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ALGORITHMS; AMYOTROPHIC LATERAL SCLEROSIS; ARTIFICIAL INTELLIGENCE; BRAIN; HUMANS; INFLAMMATION; MUTATION; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84929866065     PISSN: 18244785     EISSN: 18271936     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Rowland LP. Amyotrophic lateral sclerosis: human challenge for neuroscience. Proc Natl Acad Sci USA 1995;92:1251-3.
2. Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler 2009;10:310-23.
3. Abrahams S, Goldstein LH, Suckling J, Ng V, Simmons A, Chitnis X et al. Frontotemporal white matter changes in amyotrophic lateral sclerosis. J Neurol 2005;252:321-31.
4. Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998;23:249-56.
5. Zhang J, Yin X, Zhao L, Evans AC, Song L, Xie B et al. Regional alterations in cortical thickness and white matter integrity in amyotrophic lateral sclerosis. J Neurol 2014;261:412-21.
6. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001;344:1688-700.
7. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A populationbased study. Arch Neurol 2000;57:1171-6.
8. De Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008;119:497-503.
9. Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-9.
10. Turner MR, Agosta F, Bede P, Govind V, Lule D, Verstraete E. Neuroimaging in amyotrophic lateral sclerosis. Biomark Med 2012;6:319-37.
11. Kuipers-Upmeijer J, Dejager AE, Hew J M, Snoek JW, Van Weerden TW. Primary lateral sclerosis: clinical, neurophysiological, and magnetic resonance findings. J Neurol Neurosurg Psychiatry 2001;71:615-20.
12. Tartaglia MC, Rowe A, Findlater K, Orange JB, Grace G, Strong MJ. Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up. Arch Neurol 2007;64:232-6.
13. Cosottini M, Giannelli M, Sicilian G, Lazzarotti G, Michelassi MC, Del Corona A et al. Diffusion-tensor MR imaging of corticospinal tract in amyotrophic lateral sclerosis and progressive muscular atrophy. Radiology 2005;237:258-64.
14. Sach M, Winkler G, Glauche V, Liepert J, Heimbach B, Koch MA et al. Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. Brain 2004;127:340-50.
15. Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. OrphanetJRareDis 2009;4:3.
16. Patronas NJ, Di Chiro G, Smith BH, De La Paz R, Brooks RA, Milam HL et al. Depressed cerebellar glucose metabolism in supratentorial tumors. Brain Res 1984;291:93-101.
17. Cistaro A, Cuccurullo V, Quartuccio N, Pagani M, Valentini MC, Mansi L. Role of PET and SPECT in the study of amyotrophic lateral sclerosis. Biomed Res Int 2014;2014:237437.
18. Abrahams S, Goldstein LH, Kew JJ, Brooks DJ, Lloyd CM, Frith CD et al. Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. Brain 1996;119(Pt 6):2105-20.
19. Aquilonius SM, Jossan SS, Ekblom JG, Askmark H, Gillberg PG. Increased binding of 3H-L-deprenyl in spinal cords from patients with amyotrophic; lateral sclerosis as demonstrated by autoradiography. J Neural Transm Gen Sect 1992;89:111-22.
20. Cistaro A, Valentini MC, Chio A, Nobili F, Calvo A, Moglia C et al. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol Imaging 2012;39:251-9.
21. Hatazawa J, Brooks RA, Dalakas MC, Mansi L, Di Chiro G. Cortical motor-sensory hypometabolism in amyotrophic lateral sclerosis: a PET study. J Comput Assist Tomogr 1988;12:630-6.
22. 18F-fluoroacetate. J Nucl Med 2009;50:982-90.
23. Turner MR, Cagnin A, Turkheimer FE, Miller CC, Shaw CE, Brooks DJ et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [UC] (R)-Pklll95 positron emission tomography study. Neurobiol Dis 2004;15:601-9.
24. Turner MR, Hammers A, Al-Chalabi A, Shaw CE, Andersen PM, Brooks DJ et al. Cortical involvement in four cases of primary lateral sclerosis using [(II) C]-flumazenil PET. J Neurol 2007;254:1033-6.
25. Jeong Y, Park KC, Cho SS, Kim EJ, Kang SJ, Kim SE et al. Pattern of glucose hypometabolism in frontotemporal dementia with motor neuron disease. Neurology 2005;64:734-6.
26. Pagani M, Chio A, Valentini MC, Oberg J Nobili F, Calvo A et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology 2014;83:1067-74.
27. Van Laere K, Vanhee A, Verschueren J, De Coster L, Driesen A, Dupont P et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol 2014;71:553-61.
28. Chio A, Pagani M, Agosta F, Calvo A, Cistaro A, Filippi M. Neuroimaging in Amyotrophic Lateral Sclerosis: insight into structural and functional changes. Lancet Neurology 2014;13:1228-40.
29. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006;312:1389 92.
30. Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol 2011;10:253-63.
31. Renard D, Collombier L, Castelnovo G, Fourcade G, Kotzki PO, La Bauge P. Brain FDG-PET changes in ALS and ALS-FTD. Acta Neurol Belg 2011;111:306-9.
32. Martikainen MH, Gardberg M, Jansson L, Roytta M, Rinne JO,. Kaasinen V. Brain (1) (8) F-FDG and (D (I) C-PiB PET findings in two siblings with FTD/ALS associated with the C90RF72 repeat expansion. Neurocase 2014;20:150-7.
33. Yamakawa Y, Shimada H, Ataka S, Tamura A, Masaki H, Naka H et al. Two cases of dementias with motor neuron disease evaluated by Pittsburgh compound B-positron emission tomography. Neurol Sci 2012;33:87-92.
34. Le Forestier N, Maisonobe T, Spelle L, Lesort A, Salachas F, Lacomblez L et al. Primary lateral sclerosis: further clarification. J Neurol Sci 2001;185:95-100.
35. Pringle CE, Hudson AJ, Munoz DG, Kiernan JA, Brown WF, Ebers GC. Primary lateral sclerosis. Clinical features, neuropathology and diagnostic criteria. Brain 1992;115(Pt 2):495-520.
36. Cistaro A, Pagani M, Montuschi A, Calvo A, Moglia C, Canosa A et al. The metabolic signature of C90RF72-related ALS: FDG PET comparison with nonmutated patients. Eur J Nucl Med Mol Imaging 2014;41:844-52.
37. Ludolph AC, Langen KJ, Regard M, Herzog H, Kemper B, Kuwert T et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand 1992;85:81-9.
38. Dalakas MC, Hatazawa J, Brooks RA, Di Chiro G. Lowered cerebral glucose utilization in amyotrophic lateral sclerosis. Ann Neurol 1987;22:580-86.
39. Lloyd CM, Richardson MP, Brooks DJ, Al-Chalabi A, Leigh PN. Extramotor involvement in ALS: PET studies with the GABA (A) ligand [(II) C]flumazenil. Brain 2000;123(Pt 11):2289-96.
40. Hoffman JM, Mazziotta JC, Hawk TC, Sumida R. Cerebral glucose utilization in motor neuron disease. Arch Neurol 1992;49:849-54.
41. Kew JJ, Leigh PN, Playford ED, Passingham RE, Goldstein LH, Frackowiak RS et al. Cortical function in amyotrophic lateral sclerosis. A positron emission tomography study. Brain 1993; ll6(Pt 3):655-80.
42. Adeli A, Savica R, Lowe VJ, Vemuri P, Knopman DS, Dejesus-Hemandez M et al. The GGGGCC repeat expansion in C90RF72 in a case with discordant clinical and FDG-PET findings: PET trumps syndrome. Neurocase 2014;20:110-20.
43. Przedborski S, Dhawan V, Donaldson DM, Murphy PL, McKenna-Yasek D, Mandel FS et al. Nigrostriatal dopaminergic function in familial amyotrophic lateral sclerosis patients with and without copper/zinc superoxide dismutase mutations. Neurology 1996;47:1546-51.
44. Turner MR, Hammers A, Al-Chalabi A, Shaw CE, Andersen PM, Brooks DJ et al. Distinct cerebral lesions in sporadic and 'D90A' SODl ALS: studies with [HC]flumazenil PET. Brain 2005;128:1323-9
45. Turner MR, Osei-Lah AD, Hammers A, Al-Chalabi A, Shaw CE, Andersen PM et al. Abnormal cortical excitability in sporadic but not homozygous D90A SODl ALS. J Neurol Neurosurg Psychiatry 2005;76:1279-85.
46. Valentine JS, Doucette PA, Zittin Potter S. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu Rev Biochem 2005;74:563-93.
47. Nishitoh H, Kadowaki H, Nagai A, Maruyama T, Yokota T, Fukutomi H et al. ALS-linked mutant SODl induces ER stress- and ASKl-dependent motor neuron death by targeting Derlin-1. Genes Dev 2008;22:1451-64.
48. Pardo CA, Xu Z, Borchelt DR, Price DL, Sisodia SS, Cleveland DW. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc Natl Acad Sci USA 1995;92:954-8.
49. Takahashi H, Snow BJ, Bhatt MH, Peppard R, Eisen A, Calne DB. Evidence for a dopaminergic deficit in sporadic amyotrophic lateral sclerosis on positron emission scanning. Lancet 1993;342:1016-8..
50. Andersen PM, Forsgren L, Binzer M, Nilsson P, Ala-Hurula V, Keranen ML et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 1996;119(Pt 4):1153-72.
51. Leigh PN, Meldrum BS. Excitotoxicity in ALS. Neurology 1996;47:S221-7.
52. Yu I, Inaji M, Maeda J, Okauchi T, Nariai T, Ohno K et al. Glial cell-mediated deterioration and repair of the nervous system after traumatic brain injury in a rat model as assessed by positron emission tomography. J Neurotrauma 2010;27:1463-75.
53. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008;11:251-3.
54. Magistretti PJ. Neuron-glia metabolic coupling and plasticity. J Exp Biol 2006;209:2304-11.
55. Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci USA 1994;91:10625-9.
56. Johansson A, Engler H, Blomquist G et al. Evidence for astrocytosis in ALS demonstrated by [HC] (L)-deprenyl-D2 PET. J Neurol Sci 2007;255:17-22.
57. Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One 2012;7:e5294l.
58. Wang S, Summers RM. Machine learning and radiology. Med Image Anal 2012;16:933-51.
59. Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Cavalho S et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006.
60. Filippini N, Douaud G, Mackay CE, Knight S, Talbot K, Turner MR. Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology 2010;75:1645-52.
61. Bede P, Hardiman O. Lessons of ALS imaging: Pitfalls and future directions - A critical review. Neuroimage Clin 2014;4:436-43.